AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.

AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission

September 12, 2024 Bella Czajkowski, National Correspondent Views

Beginning Oct. 1, AstraZeneca will tighten its 340B contract pharmacy restrictions to require claims data on 340B utilization at contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski